We identified 41 patients with tumors harboring an oncogenic FGFR alteration. Median age at diagnosis was 8 years (range, 6 months-26 years). Diagnoses included 11 rhabdomyosarcomas, nine low-grade ...

The significance of FGFR as an important oncogenic driver in multiple cancers is evident in the expanding array of approved FGFR inhibitors, including futibatinib and pemigatinib in cholangiocarcinoma ...

Morice, A., et al. (2025). FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia. Bone Research. doi.org/10.1038/s41413-024-00385-x.

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

In their review, the authors describe the FGFR pathway, its role in oncogenesis, current FGFR inhibitors, the role these inhibitors play in treatment cholangiocarcinoma, and the future of the field.

Please provide your email address to receive an email when new articles are posted on . Median OS favored patients treated with erdafitinib over chemotherapy (12.1 months vs. 7.8 months). Patients ...

Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to ...

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of ...

Genetic alterations in some fibroblast growth factor receptor (FGFR) genes have been associated with bladder cancers, and as many as one-third of urothelial cancers show aberrations in FGFR family ...